Stock 301096 HANGZHOU BIO-SINCERITY PHARMA-TECH CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Company Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.

Equities

301096

CNE1000056N5

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 17/06/2024 am IST 		5-day change 1st Jan Change
61.12 CNY +1.09% Intraday chart for Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. +2.83% -6.11%
22/04 Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
2023 Tranche Update on Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s Equity Buyback Plan announced on August 24, 2023. CI

Business Summary

Hangzhou Bio-Sincerity Pharma-Tech Co Ltd is a China-based company mainly engaged in comprehensive pharmaceutical technology research and development (R&D). The services provided by the Company mainly include entrusted R&D of pharmaceutical technology and transformation of independent R&D technological achievements. The entrusted R&D business provides integrated pharmaceutical R&D services such as pharmaceutical research, clinical trial and registration application for major pharmaceutical enterprises and pharmaceutical R&D investment enterprises. The transformation business of independent R&D technological achievements is based on the independent project research and development of drug R&D platform, and actively promote the transformation of independent R&D technological achievements after obtaining phased R&D achievements.

Number of employees: 1,747

Sales per Business

CNY in Million2022Weight2023Weight Delta
Transformation of Independent Research and Development Technological Achievements
38.6 %
221 36.4 % 392 38.6 % +77.66%
Preclinical Pharmaceutical Research
33.2 %
218 36.0 % 338 33.2 % +54.81%
Clinical Services
19.0 %
80 13.2 % 193 19.0 % +141.25%
CDMO
5.2 %
21 3.4 % 52 5.2 % +152.35%
Equity Share
2.9 %
58 9.5 % 30 2.9 % -48.74%
Others
1.2 %
10 1.6 % 12 1.2 % +24.41%

Sales per region

CNY in Million2022Weight2023Weight Delta
China
100.0 %
607 100.0 % 1,017 100.0 % +67.51%

Managers

Managers TitleAgeSince
Jin Fang Lou CEO
 Chief Executive Officer 56 01/15/01
Dong Bo Yan DFI
 Director of Finance/CFO 33 01/23/01
Fu Miao Hu
43 -
Bo Fan Song
35 -
Fei Jia BRD
 Director/Board Member 45 13/18/13
Hui Ye BRD
 Director/Board Member 38 01/17/01
Yi Fan Liu BRD
 Director/Board Member 39 01/15/01
Chun Neng Shao BRD
 Director/Board Member 56 01/11/01
Yi Xu IRC
 Investor Relations Contact - -

Members of the board

Members of the board TitleAgeSince
Hui Lin Li BRD
 Director/Board Member 67 26/19/26
Yong Zhou Hu BRD
 Director/Board Member 74 26/19/26
Jin Fang Lou CEO
 Chief Executive Officer 56 01/15/01
Chun Neng Shao BRD
 Director/Board Member 56 01/11/01
Yi Fan Liu BRD
 Director/Board Member 39 01/15/01
Cheng Ren BRD
 Director/Board Member 48 20/20/20
Bo Fan Song CHM
 Chairman 35 01/15/01
Fu Miao Hu CHM
 Chairman 43 01/16/01
Hui Ye BRD
 Director/Board Member 38 01/17/01
Ning Fan BRD
 Director/Board Member 30 20/22/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 108,919,903 54,969,803 ( 50.47 %) 777,300 ( 0.7136 %) 50.47 %

Shareholders

NameEquities%Valuation
Hangzhou Qinghai Management Consulting Partnership LP
5.338 %
3,700,000 5.338 % 32 M ¥
Rongtong Fund Management Co., Ltd.
4.480 %
3,105,528 4.480 % 27 M ¥
Essence Fund Co., Ltd.
3.953 %
2,740,294 3.953 % 23 M ¥
Wei Jun Wang
3.895 %
2,700,000 3.895 % 23 M ¥
Zhuji Maicheng Pharmaceutical Technology LP
3.433 %
2,380,000 3.433 % 20 M ¥
Zhejiang Nongyin Fenghuang Investment Management Co. Ltd.
2.799 %
1,940,100 2.799 % 17 M ¥
Hangzhou Yirui Equity Investment Management Partnership LP
2.597 %
1,800,000 2.597 % 15 M ¥
Zhuji Lingjing Enterprise Management Partnership LP
2.380 %
1,650,000 2.380 % 14 M ¥
Zhuji Shengyang Enterprise Management Partnership LP
2.164 %
1,500,000 2.164 % 13 M ¥
China Universal Asset Management Co., Ltd.
2.072 %
1,436,600 2.072 % 12 M ¥
NameEquities%Valuation
Chun Neng Shao
24.70 %
20,250,000 24.70 % 173 M ¥
Jin Fang Lou
20.49 %
16,800,000 20.49 % 143 M ¥

Company contact information

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd.

159 Oasis Road Donghu Street

311103, Hangzhou

+

http://www.hzbio-s.com
address Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.(301096)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Ratings for Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
61.12
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
HANGZHOU BIO-SINCERITY PHARMA-TECH CO.,LTD. Stock Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.
-6.11% 91Cr
MODERNA, INC. Stock Moderna, Inc.
+38.66% 5.28TCr
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-7.81% 3.89TCr
LONZA GROUP AG Stock Lonza Group AG
+35.43% 3.82TCr
CELLTRION, INC. Stock Celltrion, Inc.
-10.77% 2.68TCr
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.77% 2.62TCr
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-17.82% 1.99TCr
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+35.09% 1.32TCr
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 1.22TCr
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-3.05% 1.18TCr
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 301096 Stock
  4. Company Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.